PrimeRFP - AI-Powered RFP Solutions
PrimeRFP SCOUT · Federal Contract Recompete Brief

15F06724F0001158Quadrivalent FLU vaccine in prefilled syringes — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 36F79722D0178. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Nov 21, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Division 1200
Awarding office
Glaxosmithkline LLC
Recipient
Nov 21, 2024
PoP end
$190K
Obligated
$270K
Potential
325412
NAICS
6515
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

Federal
Contract number15F06724F0001158
Also listed as36F79722D0178-15F06724F0001158
AgencyDivision 1200
Awarding officeDivision 1200
Awarding agencyDepartment of Justice (DOJ)
Funding agencyDepartment of Justice (DOJ)
IncumbentGlaxosmithkline LLC
CAGE667E9
UEIFRHTPHMZMX47
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6515
Parent IDIQ / IDV36F79722D0178
Place of performanceDURHAM NC
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startJul 8, 2024
PoP end (current)Nov 21, 2024
Obligated$190K
Current value$270K
Potential value$270K

QUADRIVALENT FLU VACCINE IN PREFILLED SYRINGES, FEDERAL EXCISE TAX AND SHIPPING. DELIVER MID SEPTEMBER 2024 TO ALL FBI LOCATIONS. WILL NEED TO BE SHIPPED TO INDIVIDUAL OFFICES AT NO ADDITIONAL CHARGE. is a federal award for Division 1200 held by Glaxosmithkline LLC. Estimated value $270K ($190K obligated). Current period of performance ends Nov 21, 2024. Last award drew 1 bidder. Place of performance: DURHAM NC.

QUADRIVALENT FLU VACCINE IN PREFILLED SYRINGES, FEDERAL EXCISE TAX AND SHIPPING. DELIVER MID SEPTEMBER 2024 TO ALL FBI LOCATIONS. WILL NEED TO BE SHIPPED TO INDIVIDUAL OFFICES AT NO ADDITIONAL CHARGE.

Recompete timing

Public
● Past PoP end (638 days ago)

Current PoP ended Nov 21, 2024 (638 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies
Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%
Open full company profile →

Related awards

Same parent · incumbent
75A50125F61019
FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E
$491K
Aug 30, 2026
75A50126F61020
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…
$493K
Oct 29, 2026
15F06724F0001366
GSK TRAVEL VACCINES
$115K
Dec 31, 2026
15F06726F0000234
GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187
$105K
Dec 31, 2026
75A50124F61014
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …
$18.4M
Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 15F06724F0001158?

15F06724F0001158 (Quadrivalent FLU vaccine in prefilled syringes) is a Division 1200 award with a potential value of $270K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 15F06724F0001158?

Division 1200 awarded 15F06724F0001158 to Glaxosmithkline LLC (potential $270K).

Who is the incumbent on 15F06724F0001158?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Nov 21, 2024.

When does Glaxosmithkline LLC’s 15F06724F0001158 come up for recompete?

SCOUT tracks a period-of-performance end of Nov 21, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/15F06724F0001158